Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of CS6253 in Healthy Volunteers and APOE4 Carriers
NCT05965414Phase 1Completed
- Sponsor
- Artery Therapeutics, Inc.
- Start
- Oct 2023
- Primary completion
- Jul 2024
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in Alzheimer's disease (AD) comparing CS6253 with Placebo (2 arms). Primary endpoints: Safety and tolerability of CS6253 at Day 13, Plasma Area Under the Curve from time zero to last quantifiable concentration at 72 hours and 8 more. Started Oct 2023; status: completed.
02
Drugs
CS-6253
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT05965414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05965414.